

**Skuld-Tech: Genomics biomarkers for diagnostic/drug tandem purpose.**  
 Didier Ritter, CEO, SKULD-TECH

<p><b>Contact of the speaker</b>  <b>Address :</b>  <b>Cell phone :</b>  <b>Email :</b>  <b>Website:</b></p>	<p>Didier RITTER          134 Rue du Curat – Bat Amarante – 24090 MONTPELLIER - FRANCE          + 33 (0)6 62 636 396  <a href="mailto:ritter@skuldtech.com">ritter@skuldtech.com</a>  <a href="http://www.skuldtech.com">www.skuldtech.com</a></p>
<p><b>Executive Summary of the presentation</b></p>	<p>Because we are all different one size-all-fits medicine is quite irrational and out of date.          Over the years medications have been prescribed mostly by trial-and-error to reach the best dose for each patient. Typically, doctors diagnosed a condition and then selected what they believed was the most promising drug for treatment. If one didn't work, they'd try another.</p> <p>By using "genomics" biomarkers, the identification of genes and how they relate to drug treatment, it is now possible to treat patients based on the actual biology of a disease and not just according to symptoms, and as an individual, not just a member of a population. The strategy rests on patients sorting into narrower diagnostic categories that correlate more strongly with the efficacy of specific therapies or preventive measures.</p> <p>Skuld-Tech's platforms are involved in genomics biomarkers discovery to pinpoint individuals at high risk of the more common side effects or with a high probability of non-response. Skuld-Tech's tools have been applied to identify new biomarkers involved in oncology to tailor treatment to patient personal polymorphism and to individual profile resistance increasing the curing and remission probabilities.</p> <p>Skuld-Tech's genomic biomarkers could lead doctors and patients through better-informed choices about treatment to decide which drug to use, whether to lower a dose, or whether closer monitoring of the patient for side effects is needed.</p> <p>Based on digital gene expression approach which rests on high throughput sequencing systems, Skuld-Tech's key enabling technologies are advanced in genomics and molecular biology. These technological approaches offer the potential to radically improve the ability to characterize susceptibility to disease and to treatment effects.</p>
<p><b>Actors and Partners (including international)</b></p>	<p>Skuld-Tech is involved in several international research programs and international partnerships including both private and public research teams from more than 20 different countries.          Skuld-Tech's partners include research institutes, universities and private companies.</p>
<p><b>Funding</b></p>	<p>Skuld-Tech funding is split into 2 sources of revenues:          - Services provided in genomics and especially in gene profiling</p>

	<p>and related bioinformatics analysis,</p> <ul style="list-style-type: none"> <li>- Research programs granted by European Union, French funding organisms, AIEA...</li> </ul>
<p><b>Current Needs / Objectives (fund, partners, ...)</b></p>	<p>Skuld-Tech objective is to develop theranostics solutions and to explore the marketing tandem of genomics biomarkers and therapeutics. Therefore, Skuld-Tech looks for industrial partners developing drug discovery pipeline to collaborate on genomics-based diagnostic/drug tandem. Skuld-Tech offers its 10 years background in genomic biomarkers discovery for Companion diagnosis purpose.</p>